Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Chief Commercial Officer | January 16, 2023 | January 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MADRIGAL PHARMACEUTICALS, INC.
Report date January 16, 2023 · Filed January 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,001 |
Reported balance
After 2023-01-16 transaction · row 1
1 source rowRow 1 · 2023-01-16 · Grant · Acquired 15,001 · Balance 15,001 F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2023 Filed Jan 19, 2023 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 15,001 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-002099 · doc4.xml · nonDerivative · entry 1 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,001 F1 · kind: Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $60.26 | $0.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · derivative · entry 20 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F2 · derivative.exercise_date: All shares issued pursuant to the exercise of the options reported herein represent 30,000 shares underlying an overall option award of 60,000 shares. All exercised options had vested. As to the overall option for 60,000 shares, 25% of the shares underlying the option vested on April 1, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 100 | $284.65 | $28,465.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 19 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $283.43 | $113,372.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 18 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.11 to $283.83, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 400 | $282.13 | $112,852.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 17 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.20, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,000 | $280.92 | $280,920.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 16 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.61 to $281.44, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,620 | $279.96 | $733,495.20 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 15 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.56 to $280.42, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,003 | $279.15 | $838,287.45 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 14 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,520 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.53 to $279.50, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 700 | $277.83 | $194,481.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 13 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,523 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.49 to $278.13, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 700 | $276.67 | $193,669.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 12 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,223 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.40 to $277.31, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 811 | $275.70 | $223,592.70 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 11 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,923 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.24 to $276.23, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,019 | $274.56 | $828,896.64 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 10 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,734 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.19 to $275.13, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,471 | $273.54 | $675,917.34 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 9 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,753 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.04 to $274.01, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,534 | $272.68 | $1,509,011.12 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 8 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,224 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.04 to $273.02, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,084 | $271.54 | $565,889.36 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 7 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,758 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.04 to $272.01, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,069 | $270.56 | $559,788.64 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 6 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,842 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.04 to $271.01, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,476 | $269.61 | $397,944.36 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 5 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,911 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.01 to $269.95, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,913 | $268.50 | $513,640.50 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 4 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,387 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.00 to $268.82, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,107 | $267.47 | $296,089.29 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 3 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,300 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.98 to $267.85, inclusive. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 593 | $266.04 | $157,761.72 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 2 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,407 F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.76 to $266.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 01:00 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 30,000 | $60.26 | $1,807,800.00 |
DisclosureSEC source: 0000899243-22-039463 · doc4.xml · nonDerivative · entry 1 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 01:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $87.09 | $0.00 |
DisclosureSEC source: 0000899243-22-007775 · doc4.xml · derivative · entry 1 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2023) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
| February 22, 2021 Filed Feb 23, 2021 18:31 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $119.49 | $0.00 |
DisclosureSEC source: 0000899243-21-007761 · doc4.xml · derivative · entry 1 Sukhija Remy · CIK 0001806949 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of the date of grant (02/22/2022) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.